Here's What Key Metrics Tell Us About The Cooper Companies (COO) Q3 Earnings

The Cooper Companies (COO) reported Q3 2025 revenue of $1.06 billion, a 5.7% year-over-year increase that slightly missed consensus estimates by 0.5%, while EPS of $1.10 surpassed expectations by 2.8%. Key operational highlights included strong 13.9% year-over-year revenue growth in EMEA and a 9.9% increase in CVI-Toric and multifocal sales, despite Americas and Asia Pacific revenues falling short of analyst projections. Although the stock has underperformed the S&P 500 over the past month, it holds a Zacks Rank #2 (Buy), indicating potential near-term market outperformance.

Analysis

The Cooper Companies (COO) presented a mixed financial picture for its third quarter of 2025, characterized by bottom-line outperformance but top-line weakness and significant divergence in segment performance. While the company reported a 5.7% year-over-year revenue increase to $1.06 billion and an EPS of $1.10 that beat the consensus estimate by 2.8%, the total revenue figure missed analyst expectations by 0.5%. A detailed review of key metrics reveals that this performance was heavily reliant on the EMEA region, which saw robust revenue growth of 13.9% YoY, substantially beating estimates. This strength was offset by considerable underperformance in the Americas, where revenue of $286 million fell well short of the $311.49 million estimate, and in Asia Pacific, which grew a mere 0.7%. Similarly, within product categories, higher-value segments like CVI's Toric and multifocal lenses (+9.9% YoY) and CSI's Fertility business (+6.0% YoY) exceeded expectations, while larger segments such as CVI's Sphere lenses and CSI's Office and surgical products missed their respective forecasts. This uneven performance, coupled with the stock's -0.1% return over the past month against the S&P 500's +1.3% gain, suggests investor apprehension despite the positive Zacks Rank #2 (Buy) designation.

Key Decisions for Investors

• Investors should closely monitor whether the high-growth segments, specifically EMEA revenue and sales from Toric/multifocal lenses and Fertility products, can sustain their momentum to compensate for the pronounced weakness in the Americas and other core product lines.
• The significant revenue miss in the Americas and stagnating growth in the Asia Pacific region represent key risk factors; future earnings reports should be scrutinized for any signs of stabilization or further deterioration in these major markets.
• Given the contradictory signals of an EPS beat against a revenue miss and underlying operational weakness, a neutral or hold position may be prudent until there is greater clarity on the company's ability to drive broader, more consistent growth across its portfolio.